We are live on ! Find out more
AG

Artal Group Portfolio holdings

AUM $1.01B
1-Year Est. Return 29.84%
This Fund
S&P 500
This Quarter Est. Return
+16.39%
1 Year Est. Return
+29.84%
3 Year Est. Return
+144%
5 Year Est. Return
+76.57%
10 Year Est. Return
+1,417.6%
AUM
$2.34B
AUM Growth
+$471M
Cap. Flow
+$471M
Cap. Flow %
20.11%
Top 10 Hldgs %
49.6%
Holding
148
New
13
Increased
17
Reduced
7
Closed
13

Top Buys

Rank Stock Value
1
APLS
Apellis Pharmaceuticals
APLS
+$59.2M
2
LXRX icon
Lexicon Pharmaceuticals
LXRX
+$51.5M
3
SWTX
SpringWorks Therapeutics
SWTX
+$33.1M
4
KRTX
Karuna Therapeutics, Inc. Common Stock
KRTX
+$25.3M
5
KLRS
Kalaris Therapeutics
KLRS
+$22M

Top Sells

Rank Stock Value
1
ARGX icon
argenx
ARGX
+$92.6M
2
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$87.5M
3
SGEN
Seagen Inc. Common Stock
SGEN
+$28.5M
4
CYTK icon
Cytokinetics
CYTK
+$13.2M
5
BLU
BELLUS Health Inc.
BLU
+$10.6M

Sector Composition

Rank Sector Weight
1 Healthcare 77.68%
2 Consumer Discretionary 2.9%
3 Financials 0.65%
4 Consumer Staples 0.17%
5 Industrials 0.16%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SLDB icon
101
Solid Biosciences
SLDB
$789M
$1.4M 0.06%
200,000
– –
TCRR
102
DELISTED
TCR2 Therapeutics Inc. Common Stock
TCRR
$1.35M 0.06%
750,000
– –
XLO icon
103
Xilio Therapeutics
XLO
$59.8M
$1.31M 0.06%
32,143
– –
MREO
104
Mereo BioPharma
MREO
$50M
$1.29M 0.06%
1,500,000
– –
ADAG
105
Adagene
ADAG
$241M
$1.28M 0.05%
1,000,000
– –
ORIC icon
106
Oric Pharmaceuticals
ORIC
$1.19B
$1.28M 0.05%
400,000
– –
AXLA
107
DELISTED
Axcella Health Inc. Common Stock
AXLA
$1.22M 0.05%
28,500
– –
CRDF icon
108
Cardiff Oncology
CRDF
$60.9M
$1.16M 0.05%
750,000
– –
IRWD icon
109
Ironwood Pharmaceuticals
IRWD
$596M
$1.15M 0.05%
110,532
– –
IGMS
110
CALL
DELISTED
IGM Biosciences
IGMS
$1.14M 0.05%
50,000
– –
CRBU icon
111
Caribou Biosciences
CRBU
$144M
$1.11M 0.05%
105,347
– –
ARAV
112
DELISTED
Aravive, Inc. Common Stock
ARAV
$1.07M 0.05%
1,311,291
– –
MRNS
113
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
$1.04M 0.04%
157,000
-843,000
-84% -$5.19M
SPRO icon
114
Spero Therapeutics
SPRO
$68.3M
$1M 0.04%
500,000
– –
HARP
115
DELISTED
Harpoon Therapeutics, Inc. Common Stock
HARP
$970K 0.04%
100,000
– –
LVTX
116
DELISTED
LAVA Therapeutics
LVTX
$914K 0.04%
200,000
– –
CRIS icon
117
Curis
CRIS
$9.76M
$910K 0.04%
3,250
– –
ORTX
118
DELISTED
Orchard Therapeutics plc American Depositary Shares
ORTX
$902K 0.04%
180,386
– –
RUBY
119
DELISTED
Rubius Therapeutics, Inc
RUBY
$886K 0.04%
2,042,666
-1,658,914
-45% -$1.24M
AVTR icon
120
Avantor
AVTR
$9.66B
$882K 0.04%
+45,000
New +$1.21M
OLMA icon
121
Olema Pharmaceuticals
OLMA
$983M
$719K 0.03%
260,500
– –
NEXI
122
DELISTED
NexImmune, Inc. Common Stock
NEXI
$666K 0.03%
48,000
– –
INKT icon
123
MiNK Therapeutics
INKT
$52.3M
$611K 0.03%
28,959
– –
MTCR
124
DELISTED
Metacrine, Inc. Common Stock
MTCR
$449K 0.02%
924,898
– –
HIPO icon
125
Hippo Holdings
HIPO
$779M
$445K 0.02%
24,000
– –
2 3 4
5
6

Similar funds

BCM
Bronte Capital Management Bondi Junction, Australia $1.01B AUM 47.99% 1-Year Est. Return
GA
GRS Advisors Chicago, Illinois $1.01B AUM 13.12% 1-Year Est. Return
EPAM
Euro Pacific Asset Management Dorado, Puerto Rico $1.01B AUM 79.26% 1-Year Est. Return
WA
Wealth Alliance Mellville, New York $1.01B AUM 19.71% 1-Year Est. Return
CT
Coastline Trust Providence, Rhode Island $1.01B AUM 22.57% 1-Year Est. Return
AH
Allen Holding New York $1.01B AUM 27.61% 1-Year Est. Return
PIM
Provident Investment Management Novi, Michigan $1.01B AUM 9.4% 1-Year Est. Return
MAM
Melqart Asset Management London, United Kingdom $1.01B AUM 84.85% 1-Year Est. Return

Artal Group's Q3 2022 Portfolio in Review

As of Q3 2022, Artal Group held 148 positions worth $2.34B, up 25% from $1.87B the previous quarter. Its ten largest holdings account for 50% of the portfolio.

Artal Group deployed $471M of net new capital in Q3 2022, opening 13 new positions and adding to 17 existing holdings. Its largest new stake was Apellis Pharmaceuticals: 1,000,000 shares worth $68.3M.

By sector, the portfolio is most concentrated in Healthcare at 78% of assets, down from 89% a quarter earlier, followed by Consumer Discretionary and Financials.

On the sell side, the largest reduction was argenx, an estimated $92.6M trimmed.

  • Artal Group's largest Q3 2022 buy was Apellis Pharmaceuticals: 1,000,000 shares worth $68.3M.
  • Artal Group added most to Lexicon Pharmaceuticals in Q3 2022, an estimated $51.5M increase.
  • Artal Group's biggest Q3 2022 reduction was argenx, cutting an estimated $92.6M.
  • Artal Group fully exited Alnylam Pharmaceuticals in Q3 2022, selling an estimated $87.5M.
  • Artal Group's ten largest holdings make up 50% of its $2.34B portfolio in Q3 2022.
  • Artal Group opened 13 new positions and closed 13 in Q3 2022.
  • Artal Group's portfolio value rose 25% quarter-over-quarter to $2.34B.

Based on Artal Group's 13F filing for Q3 2022, filed 14 Nov 2022.